Loading...
XPARERF
Market cap9.58bUSD
Dec 20, Last price  
47.96EUR
1D
0.59%
1Q
-8.65%
Jan 2017
-88.16%
Name

Eurofins Scientific SE

Chart & Performance

D1W1MN
XPAR:ERF chart
P/E
29.59
P/S
1.41
EPS
1.62
Div Yield, %
2.09%
Shrs. gr., 5y
1.58%
Rev. gr., 5y
11.49%
Revenues
6.51b
-2.94%
175,519,000233,107,000367,990,000491,773,000632,759,000640,073,000680,333,000828,934,0001,043,963,0001,225,572,0001,410,227,0001,950,074,0002,536,608,0002,971,417,0003,781,148,0004,562,800,0005,438,800,0006,717,700,0006,712,100,0006,514,600,000
Net income
310m
-49.15%
7,846,00012,393,00017,508,00017,638,00017,710,000-11,285,00023,400,00055,407,00065,924,00072,180,00079,104,00087,316,000173,997,000216,771,000223,900,000195,200,000539,400,000782,600,000610,200,000310,300,000
CFO
1.02b
-10.42%
23,371,00025,488,00030,178,00039,569,00060,036,00064,337,00084,937,000110,321,000134,161,000169,338,000212,173,000291,146,000371,843,000405,122,000543,895,000677,900,0001,223,500,0001,509,800,0001,136,300,0001,017,900,000
Dividend
Jul 03, 20240.5 EUR/sh
Earnings
Feb 25, 2025

Profile

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
URL
https://www.eurofins.com/
IPO date
Oct 24, 1997
Employees
62,000
Domiciled in
LU
Incorporated in
LU

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,514,600
-2.94%
6,712,100
-0.08%
6,717,700
23.51%
Cost of revenue
5,894,200
2,227,000
2,149,700
Unusual Expense (Income)
NOPBT
620,400
4,485,100
4,568,000
NOPBT Margin
9.52%
66.82%
68.00%
Operating Taxes
115,500
174,200
273,600
Tax Rate
18.62%
3.88%
5.99%
NOPAT
504,900
4,310,900
4,294,400
Net income
310,300
-49.15%
610,200
-22.03%
782,600
45.09%
Dividends
(191,900)
(192,100)
(129,700)
Dividend yield
1.64%
1.44%
0.59%
Proceeds from repurchase of equity
(47,800)
(1,200)
32,200
BB yield
0.41%
0.01%
-0.15%
Debt
Debt current
601,000
213,700
253,900
Long-term debt
3,904,300
3,639,400
3,039,100
Deferred revenue
1,000,000
175,800
Other long-term liabilities
1,194,000
214,900
(100)
Net debt
3,200,500
3,282,900
2,696,000
Cash flow
Cash from operating activities
1,017,900
1,136,300
1,509,800
CAPEX
(478,100)
(660,200)
(519,500)
Cash from investing activities
(681,100)
(855,900)
(1,034,200)
Cash from financing activities
495,800
(311,300)
(910,300)
FCF
292,200
3,906,800
4,008,000
Balance
Cash
1,221,200
486,600
515,300
Long term investments
83,600
83,600
81,700
Excess cash
979,070
234,595
261,115
Stockholders' equity
4,192,300
4,282,500
3,680,700
Invested Capital
8,278,830
7,616,705
6,721,285
ROIC
6.35%
60.13%
68.94%
ROCE
6.62%
56.17%
64.28%
EV
Common stock shares outstanding
197,900
199,000
200,600
Price
58.98
-12.05%
67.06
-38.36%
108.80
58.53%
Market cap
11,672,142
-12.54%
13,344,940
-38.86%
21,825,280
62.33%
EV
14,932,542
16,696,740
24,550,780
EBITDA
1,185,400
4,989,500
5,018,700
EV/EBITDA
12.60
3.35
4.89
Interest
129,400
105,600
95,000
Interest/NOPBT
20.86%
2.35%
2.08%